Literature DB >> 35402198

The effects of modified RNA-binding proteins HuR on the biological behavior of the bladder cancer T24 cell line.

Qiang Ma1,2,3, Chen Xu4, Xiaomin Han5, Xinxin Wang5, Wei Zhang5, Zhi Liu2, Rihan Wu6, Fei Wu2, Xiaohui Liu2, Tengteng Zhang5, Yan Su2,5, Kewen Zheng7,8, Yukun Wang1,3.   

Abstract

Background: In tumors, the role of human antigen R (HuR) includes regulating tumor cell proliferation, differentiation, apoptosis, angiogenesis, and lymphangiogenesis. Previous studies have revealed that the expression of HuR can be detected in bladder cancer, and is related to the biological behavior of malignancy.
Methods: T24 cells were transfected by HuR overexpression and HuR knockdown vectors, and divided into the control group, the overexpression-HuR group, and the cas9-HuR group. Cell viability was detected after 48 h by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, apoptosis was detected by Annexin V-allophycocyanin (APC)/7-aminoactinomycin D (7-AAD) double staining, cell migration was detected by Transwell assays, and the expression levels of HuR, cyclin D1, and apoptosis-related factors [i.e., B-cell lymphoma 2 (Bcl-2)] were detected by fluorescence quantitative polymerase chain reaction (PCR) and Western blot.
Results: Compared to the control group, cell viability after 48 h increased significantly in the overexpression-HuR group, and decreased significantly in the cas9-HuR group (P<0.05). The number of migrating cells increased significantly in the overexpression-HuR group, and decreased significantly in the cas9-HuR group (P<0.05). The apoptosis rate was significantly decreased in the overexpression-HuR group, and significantly increased in the cas9-HuR group (P<0.05). The messenger ribonucleic acid and protein expression levels of HuR, cyclin D1, and Bcl-2 were significantly increased in the overexpression-HuR group, and significantly decreased in the cas9-HuR group (P<0.05). Conclusions: HuR promotes the proliferation and migration of T24 cells, and inhibits cell apoptosis. The mechanism may be related to the expression of cyclin D and the apoptosis-related protein, Bcl-2. 2022 Translational Andrology and Urology. All rights reserved.

Entities:  

Keywords:  Bladder cancer; T24 cell line; human antigen R (HuR)

Year:  2022        PMID: 35402198      PMCID: PMC8984971          DOI: 10.21037/tau-22-123

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


Introduction

Bladder cancer is one of the most common types of cancers of the urinary system (1). It is estimated that >300,000 patients are diagnosed with bladder cancer every year, and >100,000 die from bladder cancer worldwide (1,2). At present, the main therapy for bladder cancer is a comprehensive treatment mode comprising a combination of surgery, radiotherapy, systemic chemotherapy, and immunity therapy. However, the majority of patients relapse after treatment, and often also suffer from a deterioration in condition (2), and the molecular mechanisms of bladder cancer recurrence and metastasis remain unclear. Although many signaling pathways, such as PI3K/AKT/mTOR, Wnt/β-catenin, and NF-κB star signaling pathways, are involved in the molecular regulation of bladder cancer recurrence and metastasis, due to the complex interaction between different signaling pathways, there is no clear evidence to fully reveal molecular mechanisms of recurrence and metastasis of bladder cancer (3). Thus, further research needs to be conducted on the genetic mechanisms of bladder cancer for therapeutic method development. Human antigen R (HuR) is a ribonucleic acid (RNA)-binding protein in the embryonic lethal abnormal vision (ELAV) family. In tumors, the role of HuR includes regulating tumor cell proliferation, differentiation, apoptosis, angiogenesis, and lymphangiogenesis (4-7). Previous studies have revealed that the expression of HuR can be detected in ovarian cancer, gastric cancer, breast cancer, cervical cancers, and other tumor tissues, and overexpression HuR in cancer cells has been associated with poor prognosis and resistance to radiotherapy and chemotherapy (4-8). In bladder cancer, high cytoplasmic HuR expression was noticed in cancer tissues, and appeared positively associated with Pathologic TNM stage and grade (9). However, the rare research was published for molecular mechanism of HuR in bladder cancer recurrence and metastasis. Hence, the role and molecular mechanism of HuR in bladder cancer still needs to be further studied and revealed. Cyclin D1 acts as a regulator of cyclin-dependent kinase (CDKs), and its main function is to promote cell proliferation (10). Among the apoptosis-related proteins, the B-cell lymphoma 2 (BCL-2) family of proteins is the most studied, and is also the most important class of anti-apoptotic protein (11,12). HuR can bind to the adenylate-uridylate-rich element (ARE) fragment of the messenger RNA (mRNA) 3’-untranslated region (3’UTR) of various genes (12). The mRNA encoding the cyclin D1 has been experimentally shown to contain an ARE fragment, and HuR may enhance the stability of the factor mRNA by binding to ARE, and thereby upregulating the expression of the above-mentioned factor protein and exerting the corresponding biological effects. Thus, the present study employed human bladder cancer T24 cells to explore the effects of HuR on the behavior of bladder cancer cells, and examine the relationship between the expression of HuR and cyclin D1 and Bcl-2. We present the following article in accordance with the MDAR reporting checklist (available at https://tau.amegroups.com/article/view/10.21037/tau-22-123/rc).

Methods

Experimental materials

The T24 human bladder transitional cell carcinoma cell line was purchased from Procell Co., Ltd., and mycoplasma testing was conducted for all cells. We also purchased the following: Roswell Park Memorial Institute (RPMI)-1640 cell culture medium, and trypsin, fetal bovine serum, 1% streptomycin (Gibco; Thermo Fisher Scientific, Inc.); pU6gRNACas9EGFP vector and pIRES2-ZsGreen vector (Addgene, Inc); Lipofectamine 2000TM transfection reagent, TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.); reverse transcription (RT)–polymerase chain reaction (PCR) kits, T4 deoxyribonucleic acid (DNA) ligase, restriction endonuclease Xho I, and EcoR I (Takara Biotechnology, Co., Ltd.); DNA gel recovery kits (Sangon Biotech, Co., Ltd.); Transwell Chamber (Corning, Incorporated); Radio immunoprecipitation assay (RIPA) lysate, bicinchoninic acid (BCA) protein concentration kits, and methylthiazolyldiphenyl-tetrazolium bromide (MTT) test kits (Beyotime, Institute of Biotechnology); apoptosis detection kits (Nanjing KeyGEN BioTECH, Co., Ltd.); HuR antibody, cyclin D1 antibody, and BCL-2 antibody (Abcam); and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) horseradish peroxidase (HRP)-labeled goat anti-rabbit secondary antibodies (ProteinTech Group, Inc.).

Cell culture

The T24 cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum and 1% streptomycin, and grown at 37 ℃ and 5% carbon dioxide (CO2). The cells were routinely subcultured when they reached ~80% confluence.

Construction of the HuR overexpression vector

The total RNA of the T24 cells was extracted according to the TRIzol kit’s instructions, complementary DNA (cDNA) was obtained by RT-PCR, and PCR was performed using the following cDNA as a template: Premix Taq 12.5 µL, 1 µL of upstream and downstream primers, 2 µL of template, and ddH2O in 25 µL of reaction system. The thermocycling conditions were 94 ℃ for 5 min, 30 cycles of 94 ℃ for 30 sec, 61 ℃ for 30 sec and 72 ℃ for 2 min, and then a 72 ℃ extension for 10 min. After electrophoresis, the gel was recovered to obtain the HuR gene fragment. The recovered HuR fragment and vector pIRES2-ZsGreen were digested with the restriction endonucleases Xho I and EcoR I, and the digested product was constructed with T4 DNA ligase to construct a HuR expression vector. The constructed HuR overexpression vector was then identified by DNA sequencing.

Construction of the HuR knockdown vector

The guide RNA (gRNA) of the HuR gene (sequence: 5'-AGAGCGATCAACACGCTGAA-3'; synthesized by Shanghai GenePharma Co., Ltd) was designed using the clustered regularly interspaced short palindromic repeats (CRISPR) online design tool (http://crispr.mit.edu/). After annealing to a double strand, the clone was ligated into the pB6gRNACas9EGFP vector digested with Bbs I. After transformation into competent escherichia coli (E. coli) DH5α, the monoclonal extraction plasmid was picked and sequenced to verify that the correctly cloned plasmid was obtained.

Quantitative (q)-PCR to detect the mRNA expression of HuR, cyclin D1, and Bcl-2

After 48 h of transfection, the control, HuR overexpression, and HuR knockdown groups were collected, and the total RNA was extracted according to the TRIzol kit’s instructions. The cDNA was obtained by RT-PCR, and the cDNA was used as a template for quantitative PCR. GAPDH was selected as the internal reference, and the relative expression of HuR, cyclin D1, and Bcl-2 mRNA was determined by the 2–∆∆Cq relative quantitative method. The primer sequences are presented in . Three independent experiments were repeated.
Table 1

Primer sequences of human antigen R (HuR), cyclin D1, B-cell lymphoma 2 (Bcl-2), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

NamePrimerSequenceSize
GAPDHForward5’-TCAAGAAGGTGGTGAAGCAGG-3’115 bp
Reverse5’-TCAAAGGTGGAGGAGTGGGT-3’
HuR Forward5’-TCATCTACAACCTGGGGCAG-3’162 bp
Reverse5’-CCATCGCGGCTTCTTCATAG-3’
Cyclin D1 Forward5’-CGGACTACAGGGGAGTTTTG-3’273 bp
Reverse5’-AGGAGGTTGGCATCGGGGT-3’
Bcl-2 Forward5’-GCCTTCTTTGAGTTCGGTGG-3’192 bp
Reverse5’-GAAATCAAACAGAGGCCGCA-3’

Western blot of analysis of HuR, cyclin D1, and Bcl-2

The cells of the control, HuR overexpression, and HuR knockdown groups were collected after 48 h. The cell lysate was lysed at 4 ℃, and centrifuged at 12,000 r/min for 30 min, and the supernatant was aspirated to obtain total protein. According to the quantitative results of the BCA assay, 10% sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) electrophoresis was conducted for 2.5 h. After the proteins were transferred to the membrane, the negative control membrane was washed in tris-buffered saline (TBS). The membranes were then blocked with 5% skim milk for 1 h at room temperature. Antibodies against HuR, cyclin D1, and Bcl-2 were incubated at 4 ℃ overnight, and the membranes were then washed for 10 min repeatedly for 3 times in TBS with Tween (TBST). The secondary antibodies were incubated for 1 h at room temperature, and then washed with TBST for 10 min 3 times. Next, the membranes were visualized by exposure development. A gray value analysis was performed using BIO-RAD Image Lab software.

MTT assays for cell proliferation activity

The MTT assays were performed 48 h after cell transfection. The control, HuR overexpression, and HuR knockdown groups were seeded in a 96-well plate. A total of 10 µL of MTT was added to each well. After incubating at 37 ℃ for 4 h, the medium was aspirated, and 150 µL of dimethyl sulfoxide was then added, and shaken on a shaker for 10 min. The absorbance value of the optical density of each well at a wavelength of 568 nm was measured with a microplate reader. Each experiment group had three replicate, and three independent experiments were repeated.

Apoptosis detection via Annexin V-APC/7-AAD double staining

The cells of the control, HuR overexpression, and HuR knockdown groups were collected at 48 h after transfection and then washed 2–3 times with pre-cooled phosphate buffered solution (PBS). The cells were adjusted to a cell concentration of 5×105/mL, and resuspended via the addition of 100 µL binding buffer. Next, 5 µL of Annexin V-APC and 5 µL of 7-AAD solution were added and mixed for 10 min at room temperature. Finally, 400 µL of 1X binding buffer was added. The samples were analyzed by flow cytometry. Three independent experiments were repeated.

Transwell assays for cell migration

The cells of the control, HuR overexpression, and HuR knockdown groups were collected 48 h after cell transfection. The cell concentration was diluted to 2×105/mL with serum-free medium. Next, 800 µL of 10% fetal bovine serum containing medium was added to a 24-well plate and placed in a Transwell chamber. Next, 200 µL of each cell suspension was inserted into the Transwell chamber, and cultured at 37 ℃ in a 5% CO2 incubator for 48 h. The Transwell insert was then removed, the chamber was carefully washed with PBS, and the cells were fixed with 70% ice ethanol solution for 1 h. The cells were stained with 0.5% crystal violet staining solution, left at room temperature for 20 min, washed with PBS, and the unmigrated cells on the upper chamber were then wiped clean with a clean cotton ball. Pictures were taken under a microscope, and the number of cells was counted. Three independent experiments were repeated.

Statistical analysis

All the experiments were repeated at least 3 times. The statistical analysis was performed using SPSS 23.0 statistical software (SPSS, Inc.) The data are expressed as the mean ± standard deviation, and an analysis of variance and a post-hoc test for multiple comparisons were used for comparisons between groups. A P value<0.05 indicated a statistically significant difference.

Results

Construction of the HuR overexpression vector and knockdown vectors

As show, the constructed HuR overexpression and knockdown vectors were sequenced and analyzed, which indicated that the inserted sequence and site were correct, and the overexpression of the target gene HuR and the knockdown vector plasmid had been successfully constructed.
Figure 1

Construction of the human antigen R (HuR) overexpression and knockdown vectors. The constructed HuR overexpression (A) and knockdown (B) vectors were sequenced and analyzed.

Construction of the human antigen R (HuR) overexpression and knockdown vectors. The constructed HuR overexpression (A) and knockdown (B) vectors were sequenced and analyzed.

Silencing and overexpression of HuR in response to HuR transfection and HuR knockdown by CRISPR-associated proteins 9 (cas9)

The protein expression levels of HuR were detected by western blotting, and are set out in . Compared to the control group, the expression level of HuR was significantly increased in the HuR overexpression group, and significantly decreased in the HuR knockdown group (P<0.01). The relative expression levels of mRNA of HuR were detected by PCR (see ). Compared to the control group, the expression level of HuR was significantly increased in the HuR overexpression group, and significantly decreased in the HuR knockdown group (P<0.01).
Figure 2

The silencing and overexpression of human antigen R (HuR) in response to HuR transfection and HuR knockdown by cas9. (A) The protein expression levels of HuR were detected by western blotting; compared to the control group, the expression level of HuR was significantly increased in the HuR overexpression group and significantly decreased in the HuR knockdown group (F=55.890, P<0.01). (B) The relative expression levels of mRNA of HuR were detected by fluorescence quantitative polymerase chain reaction (PCR). Compared to the control group, the expression level of HuR was significantly increased in the HuR overexpression group and significantly decreased in the HuR knockdown group (F=124.230, P<0.01). *, P<0.05.

The silencing and overexpression of human antigen R (HuR) in response to HuR transfection and HuR knockdown by cas9. (A) The protein expression levels of HuR were detected by western blotting; compared to the control group, the expression level of HuR was significantly increased in the HuR overexpression group and significantly decreased in the HuR knockdown group (F=55.890, P<0.01). (B) The relative expression levels of mRNA of HuR were detected by fluorescence quantitative polymerase chain reaction (PCR). Compared to the control group, the expression level of HuR was significantly increased in the HuR overexpression group and significantly decreased in the HuR knockdown group (F=124.230, P<0.01). *, P<0.05.

HuR promotes the proliferation of T24 cells

Compared to the control group, after 48 h, the cell viability was significantly increased in the HuR overexpression cells, and significantly decreased in the HuR knockdown group (P<0.01; see ).
Figure 3

Human antigen R (HuR) promotes the proliferation of T24 cells. Compared to the control group, after 48 h, cell viability was significantly increased in the HuR overexpression group and significantly decreased in the HuR knockdown group (F=1929.061, P<0.01). *, P<0.05.

Human antigen R (HuR) promotes the proliferation of T24 cells. Compared to the control group, after 48 h, cell viability was significantly increased in the HuR overexpression group and significantly decreased in the HuR knockdown group (F=1929.061, P<0.01). *, P<0.05.

HuR promotes the migration of T24 cells

Compared to the control group, the number of migrated cells was significantly increased in the HuR overexpression group, and significantly decreased in the HuR knockdown group (P<0.01; see ).
Figure 4

Human antigen R (HuR) promotes the migration of T24 cells. Compared to the control group, the number of migrated cells of HuR overexpression group was significantly increased and significantly decreased in the HuR knockdown group (F=145.982, P<0.01, all the photos magnified at ×400; all the cells were stained by crystal violet staining). *, P<0.05. (A) Control group; (B) HuR overexpression group; (C) HuR knockdown group; (D) the number of cell migrations of each group.

Human antigen R (HuR) promotes the migration of T24 cells. Compared to the control group, the number of migrated cells of HuR overexpression group was significantly increased and significantly decreased in the HuR knockdown group (F=145.982, P<0.01, all the photos magnified at ×400; all the cells were stained by crystal violet staining). *, P<0.05. (A) Control group; (B) HuR overexpression group; (C) HuR knockdown group; (D) the number of cell migrations of each group.

HuR inhibits T24 cell apoptosis

Compared to the control group, the apoptotic rate was significantly decreased in the HuR overexpression group, and significantly increased in the knockdown group (P<0.01; see ).
Figure 5

Human antigen R (HuR) inhibits T24 cell apoptosis. Compared to the control group, the apoptotic rate was significantly decreased in the HuR overexpression group and significantly increased in the knockdown group (F=665.452, P<0.01). *, P<0.05. (A) Control group; (B) HuR overexpression group; (C) HuR knockdown group; (D) each group apoptosis rate of T24 cell.

Human antigen R (HuR) inhibits T24 cell apoptosis. Compared to the control group, the apoptotic rate was significantly decreased in the HuR overexpression group and significantly increased in the knockdown group (F=665.452, P<0.01). *, P<0.05. (A) Control group; (B) HuR overexpression group; (C) HuR knockdown group; (D) each group apoptosis rate of T24 cell.

Effect of HuR on the expression of cyclin D1 and Bcl-2

The expression levels of the proteins of cyclin D1 and Bcl-2 were detected by western blotting (see ). Compared to the control group, the expression levels of cyclin D1 (P<0.01) and Bcl-2 (P<0.01) were significantly increased in the HuR overexpression group, and significantly decreased in the HuR knockdown group.
Figure 6

The effects of human antigen R (HuR) on the expression of cyclin D1 and Bcl-2. (A) The expression levels of protein of cyclin D1 and Bcl-2 were detected by western blotting. Compared to the control group, the expression levels of cyclin D1 (F=49.102.762, P<0.01) and Bcl-2 (F=265.736, P<0.01) were significantly increased in the HuR overexpression group and decreased in the HuR knockdown group. (B) The relative expression levels of mRNA of cyclin D1 and Bcl-2 were detected by fluorescence quantitative polymerase chain reaction (PCR). Compared to the control group, the expression levels of cyclin D1 (F=225.681, P<0.01) and Bcl-2 (F=202.762, P<0.01) were significantly increased in the HuR overexpression group and decreased in the HuR knockdown group. *, P<0.05.

The effects of human antigen R (HuR) on the expression of cyclin D1 and Bcl-2. (A) The expression levels of protein of cyclin D1 and Bcl-2 were detected by western blotting. Compared to the control group, the expression levels of cyclin D1 (F=49.102.762, P<0.01) and Bcl-2 (F=265.736, P<0.01) were significantly increased in the HuR overexpression group and decreased in the HuR knockdown group. (B) The relative expression levels of mRNA of cyclin D1 and Bcl-2 were detected by fluorescence quantitative polymerase chain reaction (PCR). Compared to the control group, the expression levels of cyclin D1 (F=225.681, P<0.01) and Bcl-2 (F=202.762, P<0.01) were significantly increased in the HuR overexpression group and decreased in the HuR knockdown group. *, P<0.05. The relative expression levels of mRNA of cyclin D1 and Bcl-2 were detected by PCR (see ). Compared to the control group, the expression levels of cyclin D1 (P<0.01) and Bcl-2 (P<0.01) were significantly increased in the HuR overexpression group, and significantly decreased in the HuR knockdown group.

Discussion

The progression of tumors is the result of a series of interactions between multiple genes in which tumor gene expression and function regulation have altered levels that can be regulated at the pre-transcriptional, transcriptional, and post-transcriptional levels (13-15). At the post-transcriptional level, there is a class of proteins that regulate the metabolic processes of RNA and bind to RNA, which affects the metabolism of RNA. These proteins are called RNA-binding proteins (RBPs), of which HuR is a widely studied type (16-18). HuR is a member of the ELAV family of RNA-binding proteins, located at 19p13.2, which encodes a variety of proto-oncoproteins (16-18). HuR binds to and stabilizes a partial fragment in the 3'UTR, which is widely expressed in the cytoplasm and nucleus of mammalian cells, and is mainly expressed in the nucleus in normal tissue cells. In tumor cells, there is a positive increase in HuR expression, especially in the cytosol (19,20). Young et al. reported that HuR was significantly more highly expressed in colon tumor tissues than normal colon tissues, and the increased expression of HuR promoted the development of colon cancer (21). Heinonen et al. demonstrated that in breast cancer patients with the non-breast cancer susceptibility gene 1/2 mutation, the positive rate of cytoplasmic HuR was 39.4%, and the high expression of HuR was closely associated with the number of lymph node metastases (22,23). The experimental results also suggested that HuR may be involved in lymph node metastasis (22,23). A recent study revealed that HuR was highly expressed in various tumor tissues, such as breast, gastric, esophageal, and ovarian cancer tissues (24). In the present study, the proliferation rate and migratory ability of HuR overexpression cells were significantly increased, and the apoptotic rate was decreased. The proliferation rate and migratory ability of HuR knockdown cells were significantly decreased, and the apoptotic rate was significantly increased. Thus, HuR was shown to promote the proliferation and migration and decrease the apoptosis of human bladder cancer T24 cells. The cyclin D1 gene is a proto-oncogene that plays a very important regulatory role in the cell cycle of eukaryotic cells (25,26). Cyclin D1 binds and activates cyclin dependent kinase 4 (CDK4), which is a characteristic of the G1 phase. The G1 cycle inhibitory protein [retinoblastoma protein (Rb)] is phosphorylated, and the phosphorylated Rb protein is then cleaved from its bound early 2 factor (E2F) transcription factor; in turn, the E2F transcription factor initiates the transcription of the cell-cycle gene and forms a protein complex with a cell cycle-dependent kinase, and thus, the cells pass through the cell cycle G1/S control point and enter the S phase (25,26). The expression of cyclin D1 has been shown to be significantly increased in many tumor tissues, such as breast cancer, nasopharyngeal carcinoma, lung cancer, and liver cancer tissues (27-30). In the present study, the expression of cyclin D1 was significantly increased in the HuR overexpression group, and significantly decreased in the HuR knockdown group, which suggests that the mechanism of HuR on the biological behavior of T24 cells may be related to the expression of cyclin D1 and the cell cycle. The Bcl-2 gene is also a proto-oncogene that alters the permeability of the mitochondrial outer membrane and inhibits the release of cytochrome C into the cytoplasm, thereby preventing the activation of the caspase cascade and the inhibition of apoptosis. The level of Bcl-2 protein expression regulates apoptosis. When Bcl-2 expression is high, apoptosis is inhibited. Conversely, when Bcl-2 expression is low, apoptosis is promoted. The present study revealed that compared to the control group, the expression of Bcl-2 was significantly increased in the HuR overexpression group, and the expression of Bcl-2 was significantly decreased in the HuR knockdown group, which suggests that HuR inhibits the apoptosis of human bladder cancer T24 cells, which is consistent with the conclusion that HuR inhibits apoptosis. It is indicated that HuR plays a key role in the occurrence and development of bladder cancer and may serve as a potential target for the development of new anti-bladder cancer drugs.

Conclusions

In conclusion, the RNA-binding protein HuR promotes the proliferation and migration of bladder cancer T24 cells, and inhibits apoptosis, and the mechanism may be related to its effect on the cell cycle and apoptosis. The expression of HuR is related to cyclin D1 and the apoptosis-related protein Bcl-2. Thus, the HuR gene may be a novel target gene for targeted therapy in bladder cancer patients. However, this study had some limitations. First, only one bladder cancer cell line was examined in this study. Second, experiments of both animal and human tissue samples were not conducted. Third, due to a lack of finance, only 1 apoptosis-related protein was selected for this experiment. Thus, further research, especially in-vivo studies, need to be conducted in the future. The article’s supplementary files as
  28 in total

1.  RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein.

Authors:  S S Peng; C Y Chen; N Xu; A B Shyu
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

2.  Cyclin D1 Restrains Oncogene-Induced Autophagy by Regulating the AMPK-LKB1 Signaling Axis.

Authors:  Mathew C Casimiro; Gabriele Di Sante; Agnese Di Rocco; Emanuele Loro; Claudia Pupo; Timothy G Pestell; Sara Bisetto; Marco A Velasco-Velázquez; Xuanmao Jiao; Zhiping Li; Christine M Kusminski; Erin L Seifert; Chenguang Wang; Daniel Ly; Bin Zheng; Che-Hung Shen; Philipp E Scherer; Richard G Pestell
Journal:  Cancer Res       Date:  2017-05-18       Impact factor: 12.701

Review 3.  An overview of apoptosis assays detecting DNA fragmentation.

Authors:  Pavlína Majtnerová; Tomáš Roušar
Journal:  Mol Biol Rep       Date:  2018-07-18       Impact factor: 2.316

Review 4.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

Review 5.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

6.  NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis.

Authors:  Min-Ju Kang; Byung-Kyu Ryu; Min-Goo Lee; Jikhyon Han; Jin-Hee Lee; Tae-Kyu Ha; Do-Sun Byun; Kwon-Seok Chae; Bong-Hee Lee; Hyang Sook Chun; Kil Yeon Lee; Hyo-Jong Kim; Sung-Gil Chi
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

7.  B Cell-Intrinsic Expression of the HuR RNA-Binding Protein Is Required for the T Cell-Dependent Immune Response In Vivo.

Authors:  Amy DeMicco; Martin S Naradikian; Vishal J Sindhava; Je-Hyun Yoon; Myriam Gorospe; Gerald B Wertheim; Michael P Cancro; Craig H Bassing
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

8.  Cancer cell growth suppression by a 62nt AU-rich RNA from C/EBPβ 3'UTR through competitive binding with HuR.

Authors:  Da-Quan Sun; Ying Wang; Ding-Gan Liu
Journal:  Biochem Biophys Res Commun       Date:  2012-08-16       Impact factor: 3.575

Review 9.  The autophagic network and cancer.

Authors:  Marissa D Rybstein; José Manuel Bravo-San Pedro; Guido Kroemer; Lorenzo Galluzzi
Journal:  Nat Cell Biol       Date:  2018-02-23       Impact factor: 28.824

Review 10.  Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).

Authors:  Rama Rathore; Jennifer E McCallum; Elizabeth Varghese; Ana-Maria Florea; Dietrich Büsselberg
Journal:  Apoptosis       Date:  2017-07       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.